** Brokerage UBS upgrades healthcare conglomerate CVS Health CVS.N to "buy" from "neutral," raising PT to $79 from $67
** New PT represents a ~13.2% upside to the stock's last close
** Shares of CVS up 2.2% at $70.1 premarket
** UBS says CVS has managed its Medicare Advantage plans well, giving the brokerage more confidence in its future performance
** UBS believes CVS will reduce its debt by late 2026, allowing for more share buybacks and further earnings growth
** UBS says it does not expect any major negative changes from drug pricing rules or its Star ratings in the near term
** As of last close, CVS stock up 52.8% YTD
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.